The transcatheter arterial chemoembolization combined with targeted nanoparticle delivering sorafenib system for the treatment of microvascular invasion of hepatocellular carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018Nov;68(6):394–424. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593.
   PubMed Web of Science ®Google Scholar
• Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018May;6(5):e555–e567. PMID: 29653628.
   PubMed Web of Science ®Google Scholar
• Shiani A, Narayanan S, Pena L, et al. The role of diagnosis and treatment of underlying liver disease for the prognosis of primary liver cancer. Cancer Control. 2017 Jul-Sep;24(3):1073274817729240. PMID: 28975833; PMCID: PMC5937237.
   Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941–1953. Epub 2018 Dec 6. PMID: 30350310.
   PubMed Web of Science ®Google Scholar
• Evidence-based practice guidelines for standardized pathological diagnosis of primary liver cancer in China: 2015. Zhonghua Gan Zang Bing Za Zhi. 2015 May;23(5):321–327. Chinese. PMID: 26427066.
   PubMedGoogle Scholar
• Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017Mar;34(2):153–159. Epub 2016 Dec 20. PMID: 28108047.
   PubMed Web of Science ®Google Scholar
• Chinnaratha MA, Chuang MY, Fraser RJ, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016 Feb;31(2):294–301. PMID: 26114968.
   PubMed Web of Science ®Google Scholar
• Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018May;3(5):317–325. Epub 2018 Mar 2. PMID: 29503247.
   PubMed Web of Science ®Google Scholar
• Gounder MM, Mahoney MR, Van Tine BA, et al. SFB for advanced and refractory desmoid tumors. N Engl J Med. 2018 Dec 20;379(25):2417–2428. PMID: 30575484; PMCID: PMC6447029.
   PubMed Web of Science ®Google Scholar
• Wu FQ, Fang T, Yu LX, et al. ADRB2 signaling promotes HCC progression and SFB resistance by inhibiting autophagic degradation of HIF1α. J Hepatol. 2016 Aug;65(2):314–324. Epub 2016 May 3. PMID: 27154061.
   PubMed Web of Science ®Google Scholar
• Wei L, Lee D, Law CT, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for SFB resistance in HCC. Nat Commun. 2019 Oct 15;10(1):4681. PMID: 31615983; PMCID: PMC6794322.
   PubMedGoogle Scholar
• AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018 Oct 30;67(10):1477–1492. PMID: 30215672; PMCID: PMC7190892.
   PubMed Web of Science ®Google Scholar
• Lin WF, Zhong MF, Zhang YR, et al. Prognostic role of platelet-to-lymphocyte ratio in hepatocellular carcinoma with different BCLC stages: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018 Aug 8;2018:5670949. PMID: 30158964; PMCID: PMC6109515.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016 Dec;65(6):1140–1147. Epub 2016 Jul 25. PMID: 27469901.
   PubMed Web of Science ®Google Scholar
• Li F, Chen Y, Liu S, et al. Size-controlled fabrication of zein nano/microparticles by modified anti-solvent precipitation with/without sodium caseinate. Int J Nanomedicine. 2017 Nov 10;12:8197–8209. PMID: 29184408; PMCID: PMC5689028.
   PubMed Web of Science ®Google Scholar
• Tekkeli SEK, Kiziltas MV. Current HPLC methods for assay of nano drug delivery systems. Curr Top Med Chem. 2017;17(13):1588–1594. PMID: 28017146.
   PubMed Web of Science ®Google Scholar
• Tang X, Chen L, Li A, et al. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv. 2018 Nov;25(1):1484–1494. PMID: 29916268; PMCID: PMC6058710.
   PubMed Web of Science ®Google Scholar
• Rogers N, Hermiz J, Ganji M, et al. Correlation structure in micro-ECoG recordings is described by spatially coherent components. PLoS Comput Biol. 2019 Feb 11;15(2):e1006769. PMID: 30742605; PMCID: PMC6386410.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Montal R, Torres F, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017 Jun;66(6):1166–1172. Epub 2017 Jan 26. PMID: 28131794.
   PubMed Web of Science ®Google Scholar
• Melchiorre F, Patella F, Pescatori L, et al. DEB-TACE: a standard review. Future Oncol. 2018 Dec;14(28):2969–2984. Epub 2018 Jul 10. PMID: 29987957.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang XP, Zhou TF, et al. Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis. Eur J Surg Oncol. 2019 Nov;45(11):2188–2196. Epub 2019 Jun 25. PMID: 31256949.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018 May 1;24(9):2074–2081. Epub 2018 Feb 2. PMID: 29420221.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019 Jan;72:28–36. Epub 2018 Nov 12. PMID: 30447470.
   PubMed Web of Science ®Google Scholar
• Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018 Apr;101:72–81. Epub 2018 Jan 31. Erratum in: Eur J Radiol. 2019 Mar;112:229. PMID: 29571804.
   PubMed Web of Science ®Google Scholar
• Tang X, Cai S, Zhang R, et al. Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment. Nanoscale Res Lett. 2013 Oct 17;8(1):420. PMID: 24134303; PMCID: PMC3874754.
   PubMedGoogle Scholar
• Yin D, Wangensteen KJ. Incapacitated Capicua in SFB-Resistant HCC. Cell Mol Gastroenterol Hepatol. 2020;10(2):428–429. Epub 2020 Apr 27. PMID: 32353381; PMCID: PMC7371949.
   PubMed Web of Science ®Google Scholar
• Wang H, Sun S, Zhang Y, et al. Improved drug targeting to liver tumor by SFB-loaded folate-decorated bovine serum albumin nanoparticles. Drug Deliv. 2019 Dec;26(1):89–97. PMID: 30744448; PMCID: PMC6374969.
   PubMed Web of Science ®Google Scholar
• Liu G, Kuang S, Cao R, et al. SFB kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway. FASEB J. 2019 Sep;33(9):10089–10103. Epub 2019 Jun 14. PMID: 31199678.
   PubMed Web of Science ®Google Scholar
• Yu M, Luo H, Fan M, et al. Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther. 2018 Feb 7;26(2):366–378. Epub 2017 Dec 19. PMID: 29339014; PMCID: PMC5835122.
   PubMed Web of Science ®Google Scholar
• Xia L, Teng Q, Chen Q, et al. Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma. Int J Nanomedicine. 2020 Mar 30;15:2197–2205. PMID: 32280214; PMCID: PMC7125335.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol. 2017 Jan 11;7:690. PMID: 28123387; PMCID: PMC5225101.
   PubMed Web of Science ®Google Scholar
• Yao S, Zhang J, Chen H, et al. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem. 2013 Sep;61(9):639–648. Epub 2013 May 16. PMID: 23686365; PMCID: PMC3753886.
   PubMed Web of Science ®Google Scholar